Untitled chapter

Adipose tissue is not metabolically neutral. As fat cells expand under insulin resistance, they secrete proinflammatory adipokines — T-N-F-alpha being the marquee one — that actively deplete intracellular N-A-D plus. The practitioner corpus is explicit on this point: being overweight is itself an N-A-D-plus-depleting state, and high circulating insulin compounds it through downstream effects on the salvage pathway. Sitting on top of that is NNMT — NICOTINAMIDE N-METHYLTRANSFERASE — an enzyme expressed heavily in liver but also concentrated in adipose, kidney, and brain. NNMT methylates nicotinamide into 1-methylnicotinamide, which takes N-A out of the N-A-D-plus salvage pathway entirely. Every N-A molecule NNMT consumes is one fewer that can recycle back to N-A-D plus. In a metabolically stressed Phase-1 patient, adipose tissue functions as a methyl-donor sink: it pulls N-A-D-plus precursors out of circulation and into a one-way exit while simultaneously driving the inflammatory tone that suppresses what's left. [short pause] The downstream consequences of a depleted N-A-D-plus pool: sirtuins, specifically SIRT1 and SIRT3, lose activity, mitochondrial biogenesis throttles, and muscle stem cells drift toward senescence. The Week 4 to 5 fatigue most Phase 1 patients describe — the wall — has a biochemical fingerprint, not a willpower failure. And it lands on the G-L-P 1 and G-I-P backbone at exactly the wrong moment: appetite suppression is still working, protein intake is harder to hit, and the body starts negotiating with muscle as a substrate source. [short pause] 5-Amino-1MQ is a small-molecule NNMT INHIBITOR. Oral. It does two things that make it the right Phase 2 add. First, it blocks NNMT activity — the methylation sink shuts off. N-A stays available for salvage, intracellular N-A-D plus climbs, and sirtuin signaling that protects muscle stem cells from senescence comes back online. Second, it independently promotes LIPOLYSIS in adipose tissue. The compound attacks fat from a different angle than the G-L-P 1 and G-I-P axis — mobilization of stored substrate rather than reduced intake — which is why it stacks cleanly on Phase 1 instead of competing with it. The PUSH-PULL logic that the practitioner corpus repeatedly returns to: N-M-N supplies precursor — that's the push. 5-Amino-1MQ blocks NNMT from degrading what's already there — that's the pull. Run together, intracellular N-A-D plus rises higher than either compound alone. The consensus is that this dual-pathway approach outperforms intravenous N-A-D-plus infusions at a fraction of the cost and without the niacin-flush burn. For Phase 2 specifically, this matters because N-A-D-plus-restored sirtuin activity is one of the few documented mechanisms that protects lean mass during a sustained caloric deficit. The G-L-P 1 literature has spent the last two years catching up to what practitioners running these stacks already knew: lose fat without losing the muscle, and the post-protocol metabolic floor stays high. [short pause] Here is the Phase 2 stack, layered on top of Phase 1, run across Weeks 5 to 10. First, tirzepatide continues from Phase 1. Hold at current titration, subcutaneous, weekly. This is Clinical-tier. Do not titrate up in Phase 2. The point of Phase 2 is PROTECTION, not deeper deficit. Next, 5-Amino-1MQ. Fifty to one hundred milligrams, oral, once daily in the morning, fasted. This is Experimental-tier. The practitioner corpus cites fifty to one hundred milligrams per day; some protocols push to one hundred to one hundred fifty milligrams. Take it before fasted training when used pre-workout. Then N-M-N. Ten to twenty-five milligrams, oral, with liposomal or sublingual preferred, once daily in the morning. This is Expert-tier. It pairs with 5-Amino-1MQ for the push-pull. Practitioner doses run lower than commonly circulated retail labels. Dietary protein floor: one gram per pound of lean body mass, daily, distributed across meals. Expert-tier. Non-negotiable on a G-L-P 1 backbone. Appetite suppression makes this HARDER, not optional. And finally electrolytes — sodium, potassium, magnesium — dosed per labs, oral, daily. Expert-tier. Rapid fat mobilization elevates loss; cramping at Week 6 to 8 is usually this, not the peptides. A note from the corpus: it remains thin on whether to add an I-G-F 1 L-R-3 or a CJC-1295 plus ipamorelin layer concurrent with 5-Amino-1MQ in a G-L-P 1 context. Track and report. The default is to hold growth-axis compounds until Phase 3 maintenance unless lean-mass labs at Week 8 demand earlier intervention. [short pause] What you should feel. Week 5: cleaner energy in the morning fasted window. The 5-Amino-1MQ pre-workout dose is described as clean energy in the practitioner corpus — not stimulant-like, more an absence of the Phase 1 wall. Week 6: appetite suppression from the G-L-P 1 backbone holds, but hunger cues feel MORE coherent — less of the dissociated "should I be eating" state and more genuine signal. N-A-D-plus restoration normalizes hypothalamic energy sensing. Week 7 to 8: body composition shifts faster than the scale. Waist circumference and fasting glucose move ahead of weight. Lean mass holds on a DEXA scan if you run one. Week 9 to 10: fasting insulin starts to drop meaningfully. This is the lagging indicator that confirms the adipose-tissue inflammatory tone is actually resolving, not just the symptoms. [short pause] What's NOT happening yet. 5-Amino-1MQ is not replacing the G-L-P 1. It's not a standalone fat-loss tool at fifty to one hundred fifty milligrams per day — it's a sensitizer and a protector. Pulling tirzepatide because the NNMT inhibitor feels like it's doing the work is the most common Phase 2 mistake. N-A-D-plus levels do not normalize in a week. Practitioner consensus puts the meaningful intracellular rise at three to four weeks of consistent daily dosing. The mitochondrial-biogenesis downstream — more endurance, faster recovery — trails the biochemistry by another two to three weeks. 5-Amino-1MQ has limited long-term human data. The corpus labels it Experimental for exactly this reason. Phase 2 is a six-week intervention, not a forever-add. The Phase 3 maintenance chapter handles cycling. Muscle stem cell senescence does not reverse. Sirtuin reactivation slows the drift; it doesn't restore tissue you've already lost. If Phase 1 ran muscle deep, accept that floor and protect what's left. Methylation status matters. N-M-N consumes methyl groups; in patients with impaired methylation, whether genetic or driven by chronic disease, the corpus flags rising homocysteine as a tracked side effect. Pull a homocysteine at Week 8 if you ran N-M-N the full six weeks. [short pause] Practitioner consensus describes this stack. Pull the labs, watch the lean-mass marker, and adjust the 5-Amino-1MQ dose inside the fifty to one hundred fifty milligram window based on what your body composition is actually doing — not what the scale says.